Skip to Main content Skip to Navigation
Journal articles

Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study

Complete list of metadatas

https://hal.univ-antilles.fr/hal-02473455
Contributor : Denis Boucaud-Maitre <>
Submitted on : Monday, February 10, 2020 - 5:07:46 PM
Last modification on : Tuesday, February 11, 2020 - 1:11:15 AM

Identifiers

Collections

Citation

Denis Boucaud-Maitre, Jean-Jacques Altman. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study. European Journal of Clinical Pharmacology, Springer Verlag, 2016, 72 (10), pp.1275-1281. ⟨10.1007/s00228-016-2104-3⟩. ⟨hal-02473455⟩

Share

Metrics

Record views

23